Africa Eastern and Southern vs Comoros: Access to anti-retroviral drugs, male
Africa Eastern and Southern
80.8%
in 2024
Comoros
98.0%
in 2024
Africa Eastern and Southern rank
3rd
Comoros rank
1st
Access to anti-retroviral drugs, male over time
- Africa Eastern and Southern
- Comoros
How they compare
Comoros currently reports 98.0% against 80.8% in Africa Eastern and Southern, a difference of 17.2%.
That makes Comoros's figure about 1.2 times Africa Eastern and Southern's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Comoros ahead.
Africa Eastern and Southern ranks 3rd and Comoros ranks 1st of 19 groups.
Africa Eastern and Southern has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Africa Eastern and Southern | Comoros | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.9% | 0.0% | 5.9% | Africa Eastern and Southern |
| 2010s | 45.4% | 26.4% | 19.0% | Africa Eastern and Southern |
| 2020s | 75.6% | 67.4% | 8.2% | Africa Eastern and Southern |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Africa Eastern and Southern or Comoros?
- Comoros, at 98.0% against 80.8% in Africa Eastern and Southern as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Africa Eastern and Southern and Comoros?
- 17.2%, with Comoros ahead.
- How many years of comparable data are there for Africa Eastern and Southern and Comoros?
- 25 years are reported by both, from 2000 to 2024.
- How do Africa Eastern and Southern and Comoros rank globally for access to anti-retroviral drugs, male?
- Africa Eastern and Southern ranks 3rd and Comoros ranks 1st of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.